Akums Drugs IPO: Rs 680 cr via Fresh Issue - Sebi Filing
By Rediff Money Desk, NEWDELHI Feb 11, 2024 16:18
Akums Drugs and Pharmaceuticals Ltd files draft IPO papers with Sebi, aiming to raise Rs 680 crore through fresh issue and an offer-for-sale (OFS).
New Delhi, Feb 11 (PTI) Akums Drugs and Pharmaceuticals Ltd has filed draft papers with capital markets regulator Sebi to raise funds through an initial public offering (IPO).
The initial share-sale is a combination of fresh issue of equity shares worth Rs 680 crore and an offer-for-sale (OFS) of 1.86 crore shares by promoters and an existing investor, according to the draft red herring prospectus (DRHP) filed on Saturday.
Those selling shares in the OFS are Sanjeev Jain, Sandeep Jain and Ruby QC Investment Holdings Pte Ltd.
The company is looking to raise Rs 136 crore through a pre-IPO placement. If such placement is undertaken, then fresh issue size will be reduced. Proceeds from the fresh issue will be used to repay debt, fund working capital requirements of the company, pursue inorganic growth initiatives through acquisition and for general corporate purposes.
Founded in 2004, Akums is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas.
As of September 30, 2023, key clients of the company include Alembic Pharmaceuticals, Alkem Laboratories, Cipla, Dabur India, Dr. Reddy's Laboratories, Sun Pharmaceutical Industries, among others.
ICICI Securities, Axis Capital, Citigroup Global Markets India and Ambit Pvt Ltd are the running lead managers to the issue.
The initial share-sale is a combination of fresh issue of equity shares worth Rs 680 crore and an offer-for-sale (OFS) of 1.86 crore shares by promoters and an existing investor, according to the draft red herring prospectus (DRHP) filed on Saturday.
Those selling shares in the OFS are Sanjeev Jain, Sandeep Jain and Ruby QC Investment Holdings Pte Ltd.
The company is looking to raise Rs 136 crore through a pre-IPO placement. If such placement is undertaken, then fresh issue size will be reduced. Proceeds from the fresh issue will be used to repay debt, fund working capital requirements of the company, pursue inorganic growth initiatives through acquisition and for general corporate purposes.
Founded in 2004, Akums is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas.
As of September 30, 2023, key clients of the company include Alembic Pharmaceuticals, Alkem Laboratories, Cipla, Dabur India, Dr. Reddy's Laboratories, Sun Pharmaceutical Industries, among others.
ICICI Securities, Axis Capital, Citigroup Global Markets India and Ambit Pvt Ltd are the running lead managers to the issue.
Read More On:
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Vodafone Idea L
- 9.51 (+ 1.60)
- 48673707
- Rajnish Wellness
- 1.32 (+ 3.13)
- 35724941
- Srestha Finvest
- 0.68 ( 0.00)
- 26731178
- AvanceTechnologies
- 0.80 (+ 6.67)
- 12978799
- Shangar Decor
- 5.56 (+ 1.83)
- 12830779
MORE NEWS
Samsung Galaxy S25: India Manufacturing, AI...
Samsung's new Galaxy S25 series will be manufactured in India, boasts enhanced AI...
Maharashtra Inks Rs 15 Lakh Cr MoUs at Davos
Maharashtra government signs 54 MoUs worth Rs 15.70 lakh crore at Davos, including a Rs...
Karnataka Unveils New Industrial, EV Policies...
Karnataka will announce new industrial, EV and clean mobility policies at the Karnataka...